The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.
request for cryopreserved ovarian tissue transplantation;
premature ovarian failure or irregular mentrual cycles;
negative test for HIV, HBV, HCV, Treponema pallidum;
negative PAP test;
neoplastic contamination in cryopreserved ovarian tissue;
history of endometriosis;
endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
body mass index (BMI) >30 kg/m2;
Single group
Cryopreserved Ovarian Tissue Reimplantation
Procedure/SurgeryCryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Safety of Cryopreserved ovarian tissue transplantation Using Platelet-enriched Autologous Plasma
to evaluate the safety of intraovarian PRP injection in terms of absence of adverse reactions to laparoscopic ovarian tissue reimplantation surgery. Patients in early menopause or with irregular menstrual cycles who have cryopreserved their ovarian tissue at the Cryobank of Division of Gynaecology and Human Reproduction Physiopathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna will be recruited. These patients will be joined by a historical cohort of patients who have the inclusion criteria of this study and who have already undergone reimplantation of ovarian tissue as the routine clinical care procedure.
Effectiveness of Cryopreserved ovarian tissue transplantation Using Platelet-enriched Autologous Plasma
to evaluate whether the use of autologous PRP during the ovarian tissue transplantation leads to an improvement of outcomes in terms of ovarian function recovery (endocrine and reproductive functions). Patients in early menopause or with irregular menstrual cycles who have cryopreserved their ovarian tissue at the Cryobank of Division of Gynaecology and Human Reproduction Physiopathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna will be recruited. These patients will be joined by a historical cohort of patients who have the inclusion criteria of this study and who have already undergone reimplantation of ovarian tissue as the routine clinical care procedure.
Click on the lead sponsor to view all of their trials.
